U.S. pharma big copyright scrapped two experimental weight loss tablets final calendar year—a when-day by day tablet, lotiglipron, as a result of elevated liver enzymes and also a 2 times-every day pill, danuglipron, as a consequence of powerful Unwanted effects—but CEO Albert Bourla